-
)
In the rapidly advancing field of therapeutic antibody development, speed, specificity, and diversity remain crucial for successful candidate selection. Traditional methods such as hybridoma and phage ... -
)
Antibody–drug conjugates (ADCs) have emerged as “biological missiles” against cancer, achieving notable successes in multiple tumor types. For example, HER2-targeted ADCs like trastuzumab deruxtecan ( ... -
)
The rapid advancement of oligonucleotide therapeutics is pushing the boundaries of drug design, precision, and delivery. As researchers innovate new modalities and chemistries—from antisense oligonucl ... -
)
As data-intensive industries continue to scale, the pressure mounts on cloud infrastructure to deliver not just storage, but intelligent, high-throughput, cost-effective, and secure solutions. Enter f ... -
)
The U.S. life sciences industry – spanning biotechnology firms, pharmaceutical manufacturers, and research organizations – is facing unprecedented headwinds in 2025 due to new tariffs introduced by th ... -
)
The antibody-drug conjugate (ADC) development arena is experiencing a tumultuous phase marked by strategic pivots, trial disappointments, high-stakes legal clashes, and encouraging scientific wins. Re ... -
)
Isomorphic Labs, an AI-first drug design and development company spun out from Google DeepMind, has announced a landmark $600 million funding round to advance its next-generation AI drug design engine ... -
)
In a moment that will undoubtedly reverberate across the biomedical and regulatory community, Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (CBER), has announced ... -
)
Antibody-drug conjugates (ADCs) continue to gain traction as a cornerstone of targeted oncology, offering the ability to selectively deliver potent cytotoxins to tumor cells while sparing healthy tiss ... -
)
Facts about AAV producer cell lines Gene therapies hold almost unlimited promise to treat diseases that have a genetic component. Several gene therapies are commercially available, with adeno-associat ... -
)
Introduction Antibody-drug conjugates (ADCs) have revolutionized targeted cancer therapy by combining the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic agents. However, des ... -
)
Why it Matters Transferring potency assays is a complex but crucial process in the development and manufacturing of biological products, particularly in the realm of cell and gene therapies (CGTs). Th ... -
)
Hydrogels, three-dimensional polymeric networks capable of absorbing substantial amounts of water, have emerged as pivotal materials in the realm of drug delivery systems. Their structural versatility ... -
)
Introduction Antibody-drug conjugates (ADCs) have emerged as a transformative modality in oncology, enabling the targeted delivery of cytotoxic agents to tumor cells while minimizing systemic toxicity ... -
)
Case Overview: A Pioneering Treatment with Unforeseen Longevity In 2004, a four-year-old girl diagnosed with high-risk neuroblastoma was enrolled in an early-phase CAR-T clinical trial at Texas Childr ... -
)
Breakthrough in Duchenne Gene Therapy Solid Biosciences has announced promising early results from its Phase 1/2 INSPIRE DUCHENNE trial (NCT06138639) evaluating SGT-003, an investigational gene therap ... -
)
FDA Decision Expected by August 18, 2025 NOVATO, Calif., Feb. 18, 2025 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced that the U.S. Food and Drug Administration (FDA) has accepted for r ... -
)
Sarepta Therapeutics: Pioneering Genetic Medicine Sarepta Therapeutics, a biotechnology company headquartered in Cambridge, Massachusetts, is a global leader in precision genetic medicine. The company ... -
)
The biggest asset for any drug discovery organization is the ability to access and analyze insightful, contextual, and actionable data, which then informs and underpins critical decision making. New t ... -
)
Event Overview: Antibody Therapeutics Xchange | February 19, 2025 Explore the latest advancements in antibody design, engineering, and optimization. Participants will tackle pressing challenges in ant ... -
)
Optimizing Dose and Leveraging Biomarkers for Enhanced Patient Safety in Immunotherapy Trials HubXchange Immunotherapies brought together almost 40 senior-level scientists and executives from the phar ... -
)
Tumor cells have developed sophisticated mechanisms to evade the immune system, posing significant challenges to effective cancer treatment. Recent research has elucidated several key strategies emplo ... -
)
The University of Birmingham has launched Europe's first clinical trial investigating the use of an mRNA-based vaccine to combat pancreatic cancer, a significant advance in personalized cancer immunot ... -
)
In the rapidly evolving landscape of precision medicine, one of the greatest challenges lies in predicting individual patient responses to therapeutic agents. Drug efficacy and toxicity can vary widel ... -
)
The use of machine learning (ML) in the analysis of vast biological datasets is revolutionizing our approach to drug discovery, personalized medicine, and therapeutic outcome prediction. As senior sci ... -
)
Farcast Biosciences, a research solutions company and developer of the TruTumor platform—a large fragment, near-native tumor preservation and histo-culture platform enabling precision tumor microenvir ... -
)
Nanotechnology, once confined to the realm of theoretical research, is now revolutionizing biomedical science, particularly in cancer diagnostics and therapy. Nanorobots, designed with the capacity to ... -
)
BNT116, developed by BioNTech, is an advanced mRNA-based therapeutic vaccine designed specifically to target non-small cell lung cancer (NSCLC). This vaccine falls within the broader scope of BioNTech ... -
)
In the dynamic and rapidly evolving field of antibody therapeutics, the ability to identify targets with optimal therapeutic windows is a critical determinant of clinical success. The therapeutic wind ...
NEWS XCHANGE
